Domov › Rakovina prsníka › New York › Rochester
Klinické štúdie Rakovina prsníka v meste Rochester, NY
15 štúdií pre Rakovina prsníka hľadá účastníkov v zariadeniach v meste Rochester a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Prebieha náborFáza 2
- University of Rochester Medical Center, Rochester
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Prebieha nábor
- University of Rochester (URMC), Rochester
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Prebieha náborFáza 2
- Wilmot Cancer Institute, Rochester
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Prebieha náborFáza 3
- Rochester General Hospital Lipson Cancer Institute, Rochester
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Prebieha náborFáza 3
- University of Rochester Medical, Rochester
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Prebieha náborFáza 1
- Wilmot Cancer Institute, Rochester
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Prebieha náborFáza 2
- University of Rochester Medical Center, Rochester
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Prebieha náborFáza 3
- Pluta Cancer Center, Rochester
- University of Rochester, Rochester
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Prebieha náborFáza 1
- University of Rochester - Wilmot Cancer Institute, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Prebieha náborFáza 2
- University of Rochester Wilmot Cancer Institute, Rochester
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Prebieha náborFáza 3
- Wilmot Cancer Institute Radiation Oncology at Greece, Rochester
- Highland Hospital, Rochester
- Pluta Cancer Center, Rochester
- a 3 ďalších
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Prebieha nábor
- University of Rochester, Rochester
Access to Genetic Testing in Underserved Patients With Cancer
Prebieha náborVítaní zdravých dobrovoľníkov
- University of Rochester, Rochester
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
Prebieha náborFáza 2
- University of Rochester, Rochester
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Prebieha náborObservačná štúdia
- University of Rochester - Pluta Cancer Center, Rochester
Štúdie Rakovina prsníka v iných mestách
- New York City, NY136 štúdií
- Houston, TX126 štúdií
- Boston, MA112 štúdií
- Nashville, TN81 štúdií
- Los Angeles, CA73 štúdií
- Edison, NJ68 štúdií
- St. Louis, MO64 štúdií
- Queens, NY64 štúdií
- Durham, NC64 štúdií
- Chicago, IL59 štúdií
- Philadelphia, PA56 štúdií
- Dallas, TX55 štúdií
Iné štúdie v Rochester
- Akútna myeloidná leukémia16 štúdií
- Rakovina pľúc15 štúdií
- Rakovina (všetky typy)14 štúdií
- Obézita14 štúdií
- Nadváha13 štúdií
- Nemalobunkový karcinóm pľúc13 štúdií
- Rakovina prostaty10 štúdií
- Metastatická rakovina8 štúdií
- Mnohonásobný myelóm8 štúdií
- Rakovina močového mechúra7 štúdií
- Myotonická dystrofia7 štúdií
- Rakovina pankreasu7 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.